3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Sarcoma
3
Pancreatic Neoplasms
3
Breast Neoplasms
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Brain Neoplasms
2
Wilms Tumor
1
Thrombocytosis
1
Sarcoma, Ewing
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Interventions
X-Rays
4
Phantoms, Imaging
4
Cyclophosphamide
4
Specimen Handling
3
Melphalan
3
Magnetic Resonance Spectroscopy
3
Granulocyte Colony-Stimulating Factor
3
Busulfan
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
talazoparib
2
selpercatinib
2
palbociclib
2
ivosidenib
2
fludarabine
2
cabozantinib
2
Vemurafenib
2
Topotecan
2
Temozolomide
2
Sirolimus
2
Nuclear Medicine Department, Hospital
2
Nivolumab
2
LY3023414
2
Filgrastim
2
Bone Marrow Transplantation
2
trioctyl phosphine oxide
1
regorafenib
1
racotumomab
1
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Ewing
×
entrectinib
×
Genitourinary
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA